Comparative Pharmacology
Head-to-head clinical analysis: AUKELSO versus LOTRISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUKELSO versus LOTRISONE.
AUKELSO vs LOTRISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of the mammalian target of rapamycin (mTOR) kinase, specifically the mTORC1 complex, leading to inhibition of cell proliferation, angiogenesis, and glucose uptake.
Lotrisone combines betamethasone dipropionate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, and clotrimazole, an imidazole antifungal that inhibits CYP51 (lanosterol 14alpha-demethylase), disrupting ergosterol synthesis and fungal cell membrane integrity.
400 mg orally twice daily with food.
Apply a thin film to affected skin areas twice daily, morning and evening, for 2 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 24 hours (range 20–28 h), supports once-daily dosing; prolonged in severe hepatic impairment.
Clotrimazole: 3.5-6 hours (topical, minimal systemic absorption); betamethasone dipropionate: approximately 4-6 hours for betamethasone after hydrolysis.
Primarily hepatic metabolism with biliary excretion; ~20% renal elimination of unchanged drug. Fecal excretion of metabolites accounts for ~65% of total clearance.
Clotrimazole: <0.5% of dose excreted unchanged in urine; betamethasone dipropionate: primarily renal (<5% unchanged) and biliary/fecal (35-50% as metabolites).
Category C
Category C
Topical Antifungal
Topical Antifungal/Corticosteroid Combination